Mefeda (Methylphenidate Hydrochloride)

Methylphenidate hydrochloride inhibits the reuptake of norepinephrine and dopamine, increasing their levels in the synaptic cleft. The heightened neurotransmitter activity enhances cortical signaling, which improves attention, impulse control, and wakefulness, addressing the core symptoms of ADHD and narcolepsy.

The appropriate dose of Mefeda is individualized by the prescribing clinician based on factors such as age, weight, severity of symptoms, and response to therapy. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

Safety data for methylphenidate hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mefeda belongs to the central nervous system stimulant class, similar to other methylphenidate formulations and amphetamine‑based products. Compared with amphetamines, methylphenidate generally has a slightly lower risk of cardiovascular stimulation but shares common side‑effects such as appetite loss and insomnia. Choice of therapy depends on individual response and physician assessment.

Mefeda should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf‑life.

Mefeda is taken orally, usually in tablet form, as directed by the prescriber. It is typically swallowed with water and may be taken with or without food, depending on the clinician’s instructions. The exact timing and frequency are individualized for each patient.

Serious risks include cardiovascular events such as hypertension, arrhythmia, or chest pain, as well as psychiatric complications like psychosis, severe anxiety, or hallucinations. Rarely, anaphylactic reactions can occur. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical attention.

Mefeda is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors, or patients with severe cardiovascular disorders, uncontrolled hypertension, or a history of psychosis. It should also be avoided in persons with a documented history of stimulant misuse.